Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

PRIMARY OBJECTIVES:

I. To determine the effect of intensity-modulated (IM)-stereotactic radiotherapy (SRT) on the
incidence of wound infection (requiring oral/intravenous [IV] antibiotics or surgery), or
wound dehiscence.

SECONDARY OBJECTIVES:

I. To determine the effect of IM-SRT on the incidence of titanium implants as palpable
cranial defects due to scalp thinning.

II. To determine the effect of IM-SRT on the incidence of hair loss and recovery rate.

III. To determine the effect on quality of life (QoL) using European Quality of Life Five
Dimension Five Level Scale Questionnaire (EQ-5D-5L).

TERTIARY OBJECTIVES:

I. To determine if treatment of Intensity-modulated stereotactic radiotherapy (IM-SRT) in
patients with newly diagnosed grade II-IV gliomas can decrease the loss of scalp thickness in
the coronal plane in T-1W magnetic resonance (MR) images.

Inclusion Criteria:

- Patients must have histologically confirmed low or high grade glioma (grade II-IV)

- Karnosky performance status (KPS) >= 60

- Patients must have recovered from the effects of surgery; there must be a minimum of
21 days from the day of surgery to the day of protocol treatment

- Estimated survival >= 3 months

- Normal liver, kidney and bone marrow function

- Patient must sign a study specific informed consent form

- Radiation Treatment must begin ≥ 3 weeks and ≤ 8 weeks after surgery

Exclusion Criteria:

- Prior history of scalp radiation or intolerance to standard course of radiation
treatment

- Co-morbidities that would influence wound healing including diabetes (insulin
dependent) or smoking (current ongoing use)

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception

- Karnosky performance status (KPS) < 60

- Patient can't have magnetic resonance imaging (MRI) scan

- Active collagen vascular disease